Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CITHARE: Durvalumab vs Cisplatin with Radiotherapy in HPV-related Oropharyngeal Cancer
NCT03623646Phase 2Completed
- Sponsor
- Institut Claudius Regaud
- Start
- Mar 2019
- Primary completion
- Feb 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab in oropharyngeal squamous cell carcinoma (OPSCC) (2 arms), sponsored by Institut Claudius Regaud. Primary endpoint: Rate of patients alive without progression at 12 months. Started Mar 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT03623646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03623646.